By Ben Butkus

BioMérieux said this week that it has acquired French diagnostics firm Argene for up to €42.5 million ($60.1 million) in a bid to quickly add to the test menu it plans to offer on Biocartis' forthcoming molecular diagnostics platform.

In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients, BioMérieux said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.